

Non-Multidrug-Resistant, Methicillin-Resistant *Staphylococcus aureus* Causing Infection in Health-care Facilities in Southern Brazil

Ana Paula Becker^{1*}, Vlademir Vicente Cantareli¹, Fernanda CP Rossato¹, Fernanda Matsiko Inoue³, Cicero Dias^{1,2} and Pedro Alves d'Azevedo¹

¹Federal University of Health Sciences of Porto Alegre, Brazil

²Mother of God Hospital, Porto Alegre, Brazil

³Special Laboratory of Clinical Microbiology, Federal University of São Paulo, Brazil

*Corresponding author: Ana Paula Becker, Federal University of Health Sciences of Porto Alegre, Brazil, Tel: 555133038739; E-mail: anapbecker@ibest.com.br

Rec Date: April 24, 2014, Acc date: August 21, 2014, Pub date: August 23, 2014

Copyright: © 2014 Becker AP, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Community-acquired methicillin-resistant *Staphylococcus aureus* (CA-MRSA) is usually susceptible to a variety of non-beta-lactam drugs. These isolates commonly display SCCmecIV and are associated with community-acquired infections. More recently, CA-MRSA has been isolated from health-care-associated diseases. We categorize isolates resistant only to oxacillin or oxacillin plus no more than 3 non-beta-lactam antibiotics according to clinical and epidemiological characteristics, from a hospital in Porto Alegre, and performed a combination of molecular techniques including *mecA*, *SCCmec*, Panton-Valentine leukocidin (PVL) detection and Pulsed-field gel electrophoresis (PFGE). A total of twenty-five patients with non-multidrug-resistant MRSA were studied. Nineteen (76%) came from skin and soft tissue infections. All isolates presented SCCmec type IV (being 19/25 IVc) whereas the PFGE profile most frequently found was OSCP-like (15/25). The presence of international clones USA400, USA300 was also verified. Comparing the results of clonal type with source, origin, type of SCCmec, presence the PVL gene and antimicrobial resistance we observed that OSCP-like PFGE profile was associated with skin and soft tissue infections (P=0.0012) and that this clonal group was strongly associated with the presence of PVL gene (P<0.001). This study shows a clonal diversity of CA-MRSA and strengthens the concept that these isolates emerged globally from different backgrounds.

Keywords: *Staphylococcus aureus*; Methicillin-resistant; CA-MRSA; PVL; OSCP-like

Introduction

Infections caused by *Staphylococcus aureus* especially methicillin-resistant *S. aureus* (MRSA) are emerging as a public health problem [1]. Methicillin resistance in *S. aureus* is conferred by the *mecA* gene, which is itself carried in a mobile genetic element called the staphylococcal cassette chromosome *mec* (SCCmec) [2]. In recent years, the epidemiology of infections caused by MRSA is rapidly changing, with an explosive increase in the number of community-associated MRSA (CA-MRSA) causing infection in the absence of classic risk factor for MRSA diseases, making even more complex the understanding of this epidemiology [3-5]. These CA-MRSA strains appear to have rapidly disseminated among the general population and now seem to be endemic in many urban regions, causing most community *S. aureus* infections [6].

CA-MRSA strains used to be distinguished from health care-associated MRSA (HA-MRSA) by its distinct resistance profile and by molecular methods. Contrary to MRSA strains, CA-MRSA carry smaller SCCmec elements, most commonly SCCmec type IV or type V. Moreover, they frequently carry *lukS-lukF* genes encoding for the Panton-Valentine leukocidin (PVL) [7]. To further complicate the epidemiological framework, some MRSA strains associated with community infection have been noted to cause hospital infections. Outbreaks of hospital infections caused by isolates containing SCCmec type IV have been reported [8]. Given the complex epidemiology of CA-MRSA, CDC investigators have used a third category of MRSA

infections, "health care-associated, community-onset" MRSA (HACO-MRSA) infection [9]; this category includes cases that would be hospital acquired-MRSA (HA-MRSA) infections by history of health care exposure but have onset in the community.

Previous studies coming from Brazil describe infections caused by CA-MRSA isolates obtained from the community, and from patients with no healthcare-associated infection, in Porto Alegre City [10,11]. Other international clones carrying SCCmec IV have also been reported in different Brazilian cities [12]. Scribel and coworkers demonstrated health care-associated infections caused by MRSA type IV [13]. There are not systematic, nationwide studies in Brazil to detect the presence of CA-MRSA, however the presence of these microorganisms is being detected in different cities and regions of Brazil as well as in neighbor countries [14-17].

The aim of this study was to characterize non-multidrug-resistant MRSA strains isolated from hospitalized patients in Southern Brazil.

Methods

The inclusion criteria were *Staphylococcus aureus* isolates showing resistance to oxacillin or oxacillin plus no more than 3 non-beta-lactam antibiotics from May 2007 through September 2009 at Mãe de Deus Hospital, a tertiary-care hospital with approximately 180 beds in Porto Alegre, Southern Brazil. For a given patient, we examined only data from the first positive culture. Information on the following health care risk factors for MRSA was collected: culture obtained approximately 48 hours before or after admission; surgery or hospitalization in previous 12 months preceding the cultures; presence

of an invasive device at time of admission or evaluation; history of MRSA infection or colonization; dialysis or residence in a long-term care facility in the 12 months preceding the culture [9,18-20].

Isolates were defined according to criteria proposed elsewhere [9,19,20]. Isolates were further classified in 1) health care-associated community onset (HACO-MRSA)–case-patients with one or more health care risk factor but with a culture obtained \leq 48 hours after hospital admission-2) hospital-associated (HA-MRSA)–case-patients with classic healthcare-associated infections whose culture obtained $>$ 48 hours after admission with or without other health-care risk factors-3) community-associated (CA-MRSA)–case-patients without documented health care risk factors recovered at an outpatient setting or $<$ 48 hours of hospital admission.

In vitro susceptibilities were reported as minimal inhibitory concentrations and performed with the MicroScan Walk/Away system (Siemens Healthcare, Sacramento, CA) according to the protocols of the Clinical and Laboratory Standards Institute (CLSI 2010).

Gene *mecA* characterization and *SCCmec* typing were performed by multiplex polymerase chain reaction (PCR) assay according to the protocol previously developed by Zhang et al. [21] with modifications in the primers concentrations. *SCCmec* type control strains were NCTC10442 (I), N315 (II), 85/2082 (III), CA05 (IVa), 8/6-3P (IVb), MR108 (IVc), JCSC4469 (IVd) and WIS (V). The occurrence of the PVL-encoding gene *lukS-F* was performed by SYBR Green-based real-time PCR. All PCR assays were performed directly from bacterial suspensions obtained after the rapid DNA extraction method. An aliquot of 2 μ l of this suspension was added to 23 μ l of PCR mixture containing 50 mM KCl, 20 mM Tris-HCl (pH 8.4), 2.5 mM MgCl₂, 0.2 mM of each deoxynucleoside triphosphate (dATP, dUTP, dGTP, and dCTP), 1,25 unit of *Taq* DNA polymerase and various concentrations of the primers. Analysis of chromosomal DNA of MRSA isolates were performed by pulse-field gel electrophoresis (PFGE), according to protocol established by the Centers for Disease Control and Prevention (CDC, Atlanta, GA) for *S. aureus* molecular typing [22].

Gels were normalized with reference strain *S. aureus* NCTC 8325 and compared with representative strains of local and global MRSA clones: A1721/HU25 (BEC), WB72 (USA 300), MW2 (USA 400), WB49 (Oceania South Pacific Clone), HAR24 (EMRSA–15), BK2464 (New York/Japan Clone), HDE288 (Pediatric Clone/USA800). DNA profiles were interpreted by visual inspection and by UPGMA (unweighted pair-groups method using arithmetic averages) analysis based on Dice coefficients with Bionumerics software, version 5.0 (Applied-Maths, Kortrijk, Belgium). Strain relatedness was displayed as a dendrogram and a similarity coefficient of 80% was used to distinguish between lineages [22].

Statistical analysis

Statistical analysis was assessed using non-parametric methods. Fisher's exact tests were performed using software Bioestat 5.3 and significance was defined as $P < 0.01$.

Results

A total of twenty-five patients with non-multidrug-resistant MRSA were included in this study. Nineteen (76%) came from skin and soft tissue infections, whereas six isolates (24%) came from other sources, including invasive infections (isolates from blood, sputum and cerebral spinal fluid). As expected, all strains were resistant to beta-lactams and sensitive to all antibiotics tested except, occasionally, erythromycin, gentamicin and clindamycin (inducible pattern).

Most of samples, 76% (19/25) were CA-MRSA according to epidemiological data, 3/25 (12%) were HA-MRSA and 3/25 (12%) were HACO-MRSA (Table 1). Genotypic analysis showed that all samples presented with the *SCCmec* type IV gene. Most of them had the *SCCmec* type IVc (19/25), 4/25 had *SCCmec* type IVb and 2/25 harbored *SCCmec* IVa. The occurrence of the PVL-encoding gene *lukS-F* was observed in 64% of isolates (16/25).

MRSA isolate	Date of isolation	Infection site	SCCmec Type	PVL	Antimicrobial resistance	Classification*	Clonal type
wb94	may/07	Furuncle	IVc	pos	Ery	CA-MRSA	OSPC
wb95	may/07	Abscess	IVc	pos	Ery	CA-MRSA	OSPC
wb100	jun/07	Cellulitis	IVa	neg		CA-MRSA	USA300
wb102	jul/07	Sputum	IVb	neg	Gen	HA-MRSA	USA300
wb103	set/07	Folliculitis	IVc	pos	Ery	CA-MRSA	OSPC
wb104	nov/07	Cellulitis	IVc	pos	Ery	CA-MRSA	OSPC
wb105	nov/07	Abscess	IVc	pos	Ery	CA-MRSA	OSPC
wb106	dez/07	Cellulitis	IVc	neg	Ery	CA-MRSA	USA400
wb108	mar/08	Cellulitis	IVc	pos	Ery	CA-MRSA	OSPC
a4	abr/08	Varicella vesicle	IVa	neg	Cip, Ery	HA-MRSA	USA300
wb116	mai/08	Abscess	IVc	pos	Ery, Gen	CA-MRSA	OSPC
wb117	mai/08	Nasal	IVc	neg	Ery	CA-MRSA	USA400

wb120	jun/08	Blood	IVb	neg	Cli, Ery, Gen	CA-MRSA	USA300
wb121	jul/08	Cellulitis	IVb	pos	Ery, Gen	HACO-MRSA	OSPC
wb122	jul/08	Folliculitis	IVc	pos	Ery, Gen	CA-MRSA	OSPC
wb124	ago/08	Sputum	IVb	neg	Ery, Gen	CA-MRSA	USA300
wb128	set/08	Cellulitis	IVc	pos	Ery	CA-MRSA	USA300
wb129	set/08	Folliculitis	IVc	pos	Ery	CA-MRSA	OSPC
wb130	out/08	Furuncle	IVc	pos		CA-MRSA	OSPC
wb131	nov/08	Cellulitis	IVc	pos	Ery	CA-MRSA	OSPC
wb133	mai/09	Blood	IVc	neg	Cip, Gen	HA-MRSA	***
wb134	mai/09	CSF**	IVc	neg	Cip	CA-MRSA	***
wb135	mai/09	Furuncle	IVc	pos	Cli, Ery	CA-MRSA	OSPC
wb141	ago/09	Abscess	IVc	pos	Ery	HACO-MRSA	OSPC
wb142	set/09	Fistula	IVc	pos		HACO-MRSA	OSPC

*according to criteria proposed by Klevens et al. 2007.

** Cerebral spinal fluid

*** distinct from the clones used for comparison

HACO-MRSA-health care-associated community onset: cases with a health care risk factor but with a culture obtained ≤ 48 hours after hospital admission

HO-MRSA-hospital-onset: cases with culture obtained >48 hours after admission regardless of whether they also had other health-care risk factors

CA-MRSA-community-associated: cases without documented health care risk factors recovered at an outpatient setting or < 48 hours of hospital admission

Table 1: Phenotypic and genotypic analysis of MRSA isolates

PFGE analysis revealed PFGE profiles similar to the following clones: USA400 (ST1-IV), USA300 (ST-8-IV) e OSPC (ST30-IV) (Figure 1). Two isolates (wb133 and wb134) presented a PFGE profile distinct from the clones used for comparison. Comparing the results of clonal type with source, origin, type of SCCmec, presence the PVL gene and antimicrobial resistance we observed a statistical relationship

between source and PVL with clonal type (Table 2). A significant difference between the two clonal groups (OSPC vs. others) was in the sites of MRSA infection. Skin and soft tissue were the most common infection sites among OSPC clones (P=0.0012). Furthermore, the presence of PVL gene was shown to have strong correlation with the type clonal OSPC (P<0.001).

		OSCP-like (n=15)	USA 300 (n=6) USA 400 (n=2) Other clonal group (n=2)	Total (n=25)	P
Source	Skin or soft tissue related	15	4	19	0.0012
	Other sources	0	6	6	
Origin	CA-MRSA or HACO-MRSA	14	7	21	0.2668
	HA-MRSA	1	3	4	
Type of sccMec	IVa and IVb	1	5	6	0.0225
	IVc	14	5	19	
PVL	positive	15	0	16	0.0000
	negative	0	9	9	

Antibiotic resistance (other than methicillin)	none	2	1	3	1.000
	Any combination	13	9	22	

Table 2: Characteristics of non-multidrug resistant methicillin-resistant *Staphylococcus aureus* from Porto Alegre, Brazil, according to clonal group




Figure 1: PFGE analysis of non-multidrug resistant methicillin-resistant *Staphylococcus aureus* from Porto Alegre, Brazil

Discussion

The widespread use of antibiotics has accelerated the evolution of *S. aureus*, leading to the emergence of multi-drug resistant isolates in hospitals [23]. On the other hand, a dramatically increase in the incidence of community-associated MRSA (CA-MRSA) was also observed in recent years [24,25]. Besides, this CA-MRSA may cause outbreaks of healthcare-associated infection [26-28], further confounding an epidemiological definition. In our study we first categorized isolates non-multidrug-resistant MRSA, evaluate the epidemiological characteristics and then performed molecular techniques to assess the presence of SCCmec IV and PVL-encoding gene *lukS-F*. We noted that even isolates categorized as HA-MRSA harbored SCCmec IV gene. Thus, a combination of molecular methods and epidemiological data is required to differentiate CA-MRSA from HA-MRSA.

Certain clones have established themselves as the predominant cause of CA-MRSA infection in certain localities, e.g. USA-300 in the USA [29,30]. Ribeiro and coworkers demonstrated in 2005 a spread of OSCP clone in Porto Alegre [11]. A emergence of USA400 clone was reported in two hospitals in Rio de Janeiro, Brazil [16], and other study showed that OSCP isolates were not only causing community-associated infections but were also involved in health-care associated

infections in our country [13]. Our study shows three types of CA-MRSA clones (USA 300, USA400 and OSCP) circulating in Porto Alegre, thus demonstrating a clonal diversity of strains causing infections in both the community and inside the hospital. Furthermore, it was demonstrated that the all isolates belonging to OSCP-like clone caused skin and soft tissues infections, whereas isolates of other clonal groups cause may cause other type of infection ($p=0.0012$).

PVL has been proposed as a virulence determinant in CA-MRSA [31]; In a model of severe pneumonia, rabbits showed increased morbidity and mortality when infected with PVL-containing USA300 as compared to an isogenic *lukSF* mutant, indicating a significant role of PVL in the development of severe CA-MRSA pneumonia [32]. Furthermore, PVL had a significant effect in experimental CA-MRSA (USA300) osteomyelitis when assayed in rabbits [33]. However, certain studies have questioned the value of PVL as a virulence determinant. Results in rabbit skin infection models with USA300 were controversial [34] demonstrated a moderate yet significant impact of PVL on rabbit skin infection, whereas [35] failed to detect such an effect. There are no studies which test the role of PVL in the presence of infections caused by clone OSCP. In our study most isolates were PVL-positive (16/25; 64%) and interestingly this virulence determinant was found exclusively among OSCP clonal ($P<0.001$), as previously observed in other Brazilian study [12]. This may indicate that the presence of PVL-encoding gene *lukS-F* may be a marker of OSCP-like clone, not of CA-MRSA.

Our study presents some limitations, including the low number of isolates. This indicate the need in Brazil of a more comprehensive study in order to confirm some points that we observed in this study, notably the association between OSCP-like clone and skin or soft tissue infection; and the presence of PVL-encoding gene *lukS-F* in this clonal group. The detection and monitoring of non-multidrug-resistant MRSA in both hospital and community environments is crucial to better understand their epidemiology and ultimately control their dissemination.

References

1. Lowy FD (1998) *Staphylococcus aureus* infections. N Engl J Med 339: 520-532.
2. Chambers HF (2001) The changing epidemiology of *Staphylococcus aureus*? Emerg Infect Dis 7: 178-182.
3. Baggett HC, Hennessy TW, Leman R, Hamlin C, Bruden D, et al. (2003) An outbreak of community-onset methicillin-resistant *Staphylococcus aureus* skin infections in southwestern Alaska. Infect Control HospEpidemiol 24: 397-402.
4. Buckingham S, McDougal L, Cathey L, Comeaux K, Craig A, et al. (2004) Emergence of communityacquired methicillin-resistant *Staphylococcus aureus* at a Memphis, Tennessee children's hospital. Pediatr Infect Dis J 23: 619-624.
5. Dufour P, Gillet Y, Bes M, Lina G, Vandenesch F, et al. (2002) Community-acquired methicillin-resistant *Staphylococcus aureus*

- infections in France: emergence of a single clone that produces Pantone-Valentine leukocidin. Clin Infect Dis 35: 819-824.
6. Moran GJ, Amii RN, Abrahamian FM, Talan DA (2005) Methicillin-resistant *Staphylococcus aureus* in community-acquired skin infections. Emerg Infect Dis 11: 928-930.
 7. Weber JT (2005) Community-associated methicillin-resistant *Staphylococcus aureus*. Clin Infect Dis 41 Suppl 4: S269-272.
 8. Seybold U, Kourbatova E, Johnson J, Halvosa S, Wang Y, et al. (2006) Emergence of community-associated methicillin resistant *Staphylococcus aureus* USA300 genotype as a major cause of health care-associated blood stream infections. Clin Infect Dis 42: 647-656.
 9. Klevens R, Morrison M, Nadle J, Petit S, Gershman K, et al. (2007) Invasive methicillin-resistant *Staphylococcus aureus* Infections in the United States. JAMA 298: 1763-1772.
 10. Gelatti LC, Bonamigo RR, Becker AP, D Azevedo PA (2009) Methicillin-resistant *Staphylococcus aureus*: emerging community dissemination]. An Bras Dermatol 84: 501-506.
 11. Ribeiro A, Dias C, Silva-Carvalho MC, Berquo L, Ferreira FA, et al. (2005) First report of infection with community-acquired methicillin-resistant *Staphylococcus aureus* in South America. J Clin Microbiol 43: 1985-1988.
 12. Ribeiro A, Coronado AZ, Silva-Carvalho MC, Ferreira-Carvalho BT, Dias C, et al. (2007) Detection and characterization of international community-acquired infections by methicillin-resistant *Staphylococcus aureus* clones in Rio de Janeiro and Porto Alegre cities causing both community- and hospital-associated diseases. Diagn Microbiol Infect Dis 59: 339-345.
 13. Scribel LV, Silva-Carvalho MC, Souza RR, Superti SV, Kvitko CH, et al. (2009) Clinical and molecular epidemiology of methicillin-resistant *Staphylococcus aureus* carrying SCCmecIV in a university hospital in Porto Alegre, Brazil. Diagn Microbiol Infect Dis 65: 457-461.
 14. Gelatti LC, Bonamigo RR, Inoue FM, Carmo MS, Becker AP, et al. (2013) Community-acquired methicillin-resistant *Staphylococcus aureus* carrying SCCmec type IV in southern Brazil. Rev Soc Bras Med Trop 46: 34-38.
 15. Razera F, De Stefani S, Bonamigo RR, Olm GS, Dias CA, et al. (2009) CA MRSA in furunculosis: case report of southern Brazil. An Bras Dermatol 84: 515-518.
 16. Silva-Carvalho MC, Bonelli RR, Souza RR, Moreira S, dos Santos LC, et al. (2009) Emergence of multiresistant variants of the community-acquired methicillin-resistant *Staphylococcus aureus* lineage ST1-SCCmecIV in 2 hospitals in Rio de Janeiro, Brazil. Diagn Microbiol Infect Dis 65: 300-305.
 17. Pardo L, Machado V, Mollerach M, Mota MI, Tuchscher LP, et al. (2009) Characteristics of Community-Associated Methicillin-Resistant *Staphylococcus aureus* (CA-MRSA) Strains Isolated from Skin and Soft-Tissue Infections in Uruguay. Int J Microbiol.
 18. Dietrich DW, Auld DB, Mermel LA (2004) Community-acquired methicillin-resistant *Staphylococcus aureus* in southern New England children. Pediatrics 113: e347-352.
 19. Klevens RM, Morrison MA, Fridkin SK, Reingold A, Petit S, et al. (2006) Community-associated methicillin-resistant *Staphylococcus aureus* and healthcare risk factors. Emerg Infect Dis 12: 1991-1993.
 20. Schramm GE, Johnson JA, Doherty JA, Micek ST, Kollef MH (2007) Increasing incidence of sterile-site infections due to non-multidrug-resistant, oxacillin-resistant *Staphylococcus aureus* among hospitalized patients. Infect Control Hosp Epidemiol 28: 95-97.
 21. Zhang K, McClure JA, Elsayed S, Louie T, Conly JM (2005) Novel multiplex PCR assay for characterization and concomitant subtyping of staphylococcal cassette chromosome mec types I to V in methicillin-resistant *Staphylococcus aureus*. J Clin Microbiol 43: 5026-5033.
 22. McDougal LK, Steward CD, Killgore GE, Chaitram JM, McAllister SK, et al. (2003) Pulsed-field gel electrophoresis typing of oxacillin-resistant *Staphylococcus aureus* isolates from the United States: establishing a national database. J Clin Microbiol 41: 5113-5120.
 23. Sakoulas G, Moellering RC Jr (2008) Increasing antibiotic resistance among methicillin-resistant *Staphylococcus aureus* strains. Clin Infect Dis 46 Suppl 5: S360-367.
 24. Stefani S, Bongiorno D, Cafiso V, Campanile F, Crapis M, et al. (2009) Pathotype and susceptibility profile of a community-acquired methicillin-resistant *Staphylococcus aureus* strain responsible for a case of severe pneumonia. Diagn Microbiol Infect Dis 63: 100-104.
 25. Valentini P, Parisi G, Monaco M, Crea F, Spanu T, et al. (2008) An uncommon presentation of a severe invasive infection due to methicillin-resistant *Staphylococcus aureus* clone USA300 in Italy: a case report. Ann Clin Microbiol Antimicrob 7: 11.
 26. David MD, Kearns AM, Gossain S, Ganner M, Holmes A, et al. (2006) Community-associated methicillin-resistant *Staphylococcus aureus*: nosocomial transmission in a neonatal unit. J Hosp Infect 64: 244-250.
 27. Otter JA, French GL (2006) Nosocomial transmission of community-associated methicillin-resistant *Staphylococcus aureus*: an emerging threat. Lancet Infect Dis 6: 753-755.
 28. Kouyos R, Klein E, Grenfell B (2013) Hospital-Community Interactions Foster Coexistence between Methicillin-Resistant Strains of *Staphylococcus aureus*. Plos Pathogens 9: 1-14.
 29. Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, et al. (2006) Methicillin-resistant *S. aureus* infections among patients in the emergency department. N Engl J Med 355: 666-674.
 30. Tenover FC, McDougal LK, Goering RV, Killgore G, Projan SJ, et al. (2006) Characterization of a strain of community-associated methicillin-resistant *Staphylococcus aureus* widely disseminated in the United States. J Clin Microbiol 44: 108-118.
 31. Labandeira-Rey M, Couzon F, Boisset S, Brown EL, Bes M, et al. (2007) *Staphylococcus aureus* Pantone-Valentine leukocidin causes necrotizing pneumonia. Science 315: 1130-1133.
 32. Diep BA, Chan L, Tattevin P, Kajikawa O, Martin TR, et al. (2010) Polymorphonuclear leukocytes mediate *Staphylococcus aureus* Pantone-Valentine leukocidin-induced lung inflammation and injury. Proc Natl Acad Sci 107: 5587-5592.
 33. Cremieux AC, Dumitrescu O, Lina G, Vallee C, Cote JF, et al. (2009) Pantone-valentine leukocidin enhances the severity of community-associated methicillin-resistant *Staphylococcus aureus* rabbit osteomyelitis. PLoS ONE 4: e7204.
 34. Lipinska U, Hermans K, Meulemans L, Dumitrescu O, Badiou C, et al. (2011) Pantone-Valentine leukocidin does play a role in the early stage of *Staphylococcus aureus* skin infections: a rabbit model. PLoS One 6: e22864.
 35. Kobayashi SD, Malachowa N, Whitney AR, Braughton KR, Gardner DJ, et al. (2011) Comparative analysis of USA300 virulence determinants in a rabbit model of skin and soft tissue infection. J Infect Dis 204: 937-941.